Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Iritero - Philippines FDA Drug Approval Details

Approvals/Philippines FDA/Iritero

Approved

STANDARD

Iritero

Hetero Labs Limited🇵🇭 Food and Drug Administration - Philippines

Approval Date: Jul 14, 2025
Approval ID: cdc1a3efdb04dd1a
Company: Hetero Labs Limited
Type: Standard

Approval Details

Approval Id: cdc1a3efdb04dd1a
Drug Approval Philippines Name: Iritero
Product Name: Iritero
Registration Number: DRP-8210
Brand Name: Iritero
Generic Name: Irinotecan (as hydrochloride)
Dosage Form: Solution for Intravenous Infusion
Dosage Strength: 40mg/ 2mL
Manufacturer: Hetero Labs Limited
Importer: S.M.H.P. Marketing & Consultancy
Distributor: S.M.H.P. Marketing & Consultancy
Company Detail Path: /organization/hetero-labs-limited
Issuance Date: 24 January 2024
Expiry Date: 31 May 2029
Pharmacologic Category: Antineoplastic (Cell Cycle-Specific Agent)
Classification: Prescription Drug (Rx)

Active Ingredients

Approved

Quick Info

Agency

Philippines FDA

Country

🇵🇭

Approval Date

Jul 14, 2025

Approval ID

cdc1a3efdb04dd1a

Type

Standard

Back to Philippines FDA Approvals